Circulating Levels of Uric Acid and Risk for Metabolic Syndrome

Rubio-Guerra, Alberto Francisco; Morales-López, Herlinda; Garro-Almendaro, Ana Karen; Vargas-Ayala, Germán; Durán-Salgado, Montserrat Berenice; Huerta-Ramírez, Saúl; Lozano-Nuevo, José Juan

doi:10.2174/1573399812666150930122507

Cited by 27 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hyperuricemia causes gouty arthritis (Zamudio-Cuevas et al, 2015 ), kidney stones (Mirheydar et al, 2014 ) and chronic renal failure (Tsai et al, 2017 ), which significantly impact quality of life (Scire et al, 2013 ). Hyperuricemia has also been considered to be a risk factor for metabolic syndrome (Cibicková et al, 2017 ; Rubio-Guerra et al, 2017 ), diabetes mellitus (Wang et al, 2013 ), hypertension (Lyngdoh et al, 2012 ), stroke (Wu et al, 2017 ), chronic kidney disease (Ceriello et al, 2017 ) and cardiovascular disease (Qin et al, 2014 ; Amin et al, 2017 ; Moulin et al, 2017 ). Hyperuricemia is therefore a serious public health problem that should be detected early and treated.…”

Section: Introductionmentioning

confidence: 99%

Neck Circumference, a Novel Indicator for Hyperuricemia

et al. 2017

View full text Add to dashboard Cite

Background: Waist circumference has been correlated with the risk of hyperuricemia. Whether neck circumference is also associated with hyperuricemia has not been assessed. This study aimed to investigate whether neck circumference is associated with hyperuricemia.Methods: This study population from Beijing is part of the larger China-wide Risk Evaluation of Cancers in Chinese Diabetic Individuals: a lONgitudinal (REACTION) study. For this Beijing sub-center cross-sectional study, a total of 8971 subjects were recruited. Gender-specific multivariable-adjusted regression analyses were conducted to analyze the association of neck circumference and waist circumference with hyperuricemia and the association of neck circumference with serum uric acid levels in the non-hyperuricemia population.Results: After adjusting for confounding variables, regression analyses showed that neck circumference was positively associated with hyperuricemia [OR, 2.61 (1.86–3.67) for males and 3.27 (2.53–4.22) for females] in both genders; further, neck circumference was also positively associated with serum uric acid levels in non-hyperuricemia subjects [b, 2.58 (1.76–3.39) for males and 4.27 (3.70–4.84) for females] in both genders. Additionally, we demonstrated that neck circumference was similar to waist circumference in terms of the strength of association (OR, 3.03 for waist circumference vs. 2.61 for neck circumference in males, and 3.50 vs. 3.27 for females) with hyperuricemia and the ability to predict hyperuricemia (AUC, 0.63 for waist circumference vs. 0.61 for neck circumference in males, and 0.66 vs. 0.66 in females).Conclusion: Neck circumference is positively and independently associated with hyperuricemia in both genders and is also associated with serum uric acid levels in the non-hyperuricemia population.

show abstract

Section: Introductionmentioning

confidence: 99%

Neck Circumference, a Novel Indicator for Hyperuricemia

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Accumulating evidences have demonstrated that uric acid induces oxidative damage in a variety of tissues (5,6). Furthermore, hyperuricemia has been identified as an independent risk factor for various chronic conditions such as hypertension, diabetes, cardiovascular disease, metabolic syndrome, and chronic kidney disease (7)(8)(9)(10)(11). It has been recently reported an association between elevated uric acid and a hepatokine that acts as a molecular link between non-alcoholic fatty liver disease and metabolic disorders (12).…”

Section: Introductionmentioning

confidence: 99%

Effects of Uric Acid-Lowering Treatment on Glycemia: A Systematic Review and Meta-Analysis

Chen

Zha

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Background: Serum uric acid levels have been shown to be associated with increased risk of diabetes. However, it remains unclear whether uric acid-lowering therapy (ULT) is associated with improved glycemic status. This study aimed to summarize evidence from randomized controlled trials (RCTs) to investigate whether ULT reduces fasting blood glucose (FBG) and glycated hemoglobin A1c (HbA1c) levels. Methods: PubMed, Embase, and the Cochrane Library were searched from inception until April 10, 2019. Moreover, in order to maximize the search for articles on the same topic, the reference lists of included studies, relevant review articles and systematic reviews were reviewed. Parallel RCTs investigating the effect of ULT on FBG or HbA1c levels were considered for inclusion. An English language restriction was applied. Data were screened and extracted independently by two researchers. Meta-analyses were performed using random-effects models to calculate the weighted mean differences (WMDs) and 95% confidence intervals (CIs). Results: Four trials with 314 patients reported the effect of ULT with allopurinol on FBG and 2 trials with 141 patients reported the effect of ULT with allopurinol on HbA1c. Treatment with allopurinol resulted in a significant decrease in FBG (WMD: −0.61 mmol/L, 95% CI: −0.93 to −0.28), but only a trend of reduction in HbA1c (WMD: −0.47%, 95% CI: −1.16 to 0.22). Notably, the subgroup analyses showed that treatment with allopurinol was associated with reduced FBG levels in patients without diabetes (WMD: −0.60 mmol/L, 95% CI: −0.99 to −0.20), but not in patients with diabetes. In addition, the dose of allopurinol treatment ≥200 mg daily resulted in a reduction of FBG levels (WMD: −0.59 mmol/L, 95% CI: −0.95 to −0.23), whereas low-dose allopurinol (<200 mg daily) had no effect on FBG levels. Conclusions: The findings suggest that ULT with allopurinol may be effective at reducing glycemia, but such an improvement does not appear to be observed in patients with diabetes. The findings require confirmation in additional trials with larger sample sizes.

show abstract

“…Apart from hyperuricemia, several risk factors for development of gout have been postulated in different studies including genetic factors, dietary factors, alcohol consumption, diuretic use, and renal disease [4]. There are studies showing the close association of hyperuricemia or gout with metabolic syndrome [5][6][7]. Gout can be considered as a risk factor for hypertension (HTN), cardiovascular disease, chronic kidney disease (CKD), and diabe-tes [8].…”

Section: Introductionmentioning

confidence: 99%

“…Few studies suggest that uric acid contributes to increased inflammation leading to CKD progression, thus demonstrating the relationship between serum urate levels and kidney function. While hyperuricemia can cause the progression of renal disease, kidney dysfunction itself can increase serum urate levels due to glomerular damage leading to reduced excretion of serum uric acid [6,7].…”

Section: Introductionmentioning

confidence: 99%

Changes in Urinary Microalbumin Levels after Correction of Hyperuricemia in Patients with Gout: An Observational Cohort Study

Vaidya¹,

Pudasaini²,

Nakarmi³

2020

International Journal of Rheumatology

View full text Add to dashboard Cite

Background. Gout is commonly associated with metabolic syndrome. Strong association between the serum uric acid level and microalbuminuria has also been observed in various studies. Aim. To observe the change in urinary microalbumin after urate-lowering treatment in patients with gout and microalbuminuria. Methodology. A prospective, observational study was conducted at a tertiary-level rheumatic center (NCRD) in Kathmandu, Nepal. Adults diagnosed with gout using the 2015 ACR/EULAR criteria and microalbuminuria were enrolled in the study after obtaining informed consent. Sociodemographic profile and clinical history were recorded at baseline. Serum uric acid levels, spot urinary microalbumin (MAU) excretion, blood sugar, lipid profile, and blood pressure were measured at baseline, 3-month follow-up, and 6-month follow-up. A paired t-test was used to compare the change in mean MAU after treatment. Results. A total of 778 patients diagnosed with gout were screened for microalbuminuria. Among them, 114 (14.6%) had urinary microalbumin levels of >30.0 mg/L during presentation. Mean MAU level among those with microalbuminuria was 132.4±124.6 mg/L. Thirty-five patients had concomitant HTN and were put on ARBs (20 mg of telmisartan). All received 40 mg of febuxostat. In patients with ARBs, MAU reduced significantly after 3 months of treatment with ARBs. Reduction in MAU in those without ARBs was seen after the 6-month follow-up, and the change was statistically significant. Conclusions. There is significant reduction in MAU after the use of urate-lowering drugs in patients with gout.

show abstract

Circulating Levels of Uric Acid and Risk for Metabolic Syndrome

Abstract: Our results showed a significant association between hyperuricemia and metabolic syndrome in low-income young adults in Mexico. DR is associated with estimated risk of CVD in type 2 diabetic patients.

Cited by 27 publications

References 0 publications

Neck Circumference, a Novel Indicator for Hyperuricemia

Neck Circumference, a Novel Indicator for Hyperuricemia

Effects of Uric Acid-Lowering Treatment on Glycemia: A Systematic Review and Meta-Analysis

Changes in Urinary Microalbumin Levels after Correction of Hyperuricemia in Patients with Gout: An Observational Cohort Study

Contact Info

Product

Resources

About